Disagreement FDA and EMA on RSV Maternal Vaccination: Possible Consequence for Global Mortality
Publication date
2024-01-01
Authors
Willemsen, J.
Borghans, J.A.M.
Bont, Louis J
Drylewicz, Julia
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
cc_by
Abstract
The European Medicines Agency and the US Food and Drug Administration have recently approved a maternal vaccine for respiratory syncytial virus. The US Food and Drug Administration limits vaccination to later in pregnancy. Mathematical modeling demonstrates that this vaccination window may reduce the global mortality impact of the vaccine by 12%. Policymakers should carefully consider vaccine risks and benefits to safeguard vulnerable infants effectively.
Keywords
Abrysvo vaccine, EMA guidelines, FDA guidelines, LMICs, RSV, infant mortality, maternal vaccination, vaccine administration timing, vaccine impact, vaccine licensure, vaccine recommendations, Microbiology (medical), Infectious Diseases, Pediatrics, Perinatology, and Child Health
Citation
Willemsen, J E, Borghans, J A M, Bont, L J & Drylewicz, J 2024, 'Disagreement FDA and EMA on RSV Maternal Vaccination : Possible Consequence for Global Mortality', The Pediatric infectious disease journal, vol. 43, no. 1, pp. e1-e2. https://doi.org/10.1097/INF.0000000000004173